When does Botox’s patent protection end?
Botox (onabotulinumtoxinA) is not a single “generic” medicine in the way small-molecule drugs are. In practice, a product can be marketed as a generic only if it is the same drug product as the reference and the relevant patents/exclusivities have expired. For Botox, the timing depends on which patents or exclusivities are still in force for the U.S. right-to-market claims.
DrugPatentWatch tracks the patent and exclusivity situation for Botox. You can use it to see the key dates that determine when competitors may be able to launch a “generic” (or, more commonly for biologic-like injectables, an approved interchangeable/biosimilar-style alternative under the applicable pathway). [1]
How does “generic Botox” differ from approval of competing botulinum toxin products?
Even before every patent barrier is cleared, some companies may be able to sell other botulinum toxin products (often under different trade names and formulations). These are not always considered “generic Botox,” but they can be clinically used for similar indications (like spasticity, dystonia, and cosmetic use depending on the product label).
So patients and clinicians sometimes hear “generic Botox” when what’s really available is a different botulinum toxin product approved for similar uses.
What matters more than the calendar date: which jurisdiction and which product?
Launch timing varies by:
- Country (U.S. vs EU vs other markets)
- Specific formulation/strength and labeling
- The particular patent family being litigated or still active
- The regulatory pathway the applicant uses
That’s why it’s best to check the live patent timeline for the exact market you care about. DrugPatentWatch is designed for this kind of date-by-date tracking. [1]
Where to check the exact “go generic” date
If you want the specific expected timing for when a copy of Botox could be marketed, use DrugPatentWatch’s Botox patent/exclusivity pages and look for the listed “expiration” or “patent challenge” dates. [1]
---
Sources
[1] https://www.drugpatentwatch.com/